Inherent Group, LP Bridge Bio Pharma, Inc. Transaction History
Inherent Group, LP
- $107 Million
- Q3 2024
A detailed history of Inherent Group, LP transactions in Bridge Bio Pharma, Inc. stock. As of the latest transaction made, Inherent Group, LP holds 118,900 shares of BBIO stock, worth $3.94 Million. This represents 0.25% of its overall portfolio holdings.
Number of Shares
118,900Holding current value
$3.94 Million% of portfolio
0.25%Shares
0 transactions
| Quarter | Operation | Price Per share | shares change | shares Held | SEC Form |
|---|
Others Institutions Holding BBIO
# of Institutions
361Shares Held
185MCall Options Held
12.8MPut Options Held
2.09M-
Viking Global Investors LP22.1MShares$730 Million2.55% of portfolio
-
Kohlberg Kravis Roberts & Co. L.P. New York, NY19.3MShares$638 Million30.7% of portfolio
-
Vanguard Group Inc Valley Forge, PA14.9MShares$493 Million0.01% of portfolio
-
Black Rock Inc. New York, NY12.4MShares$412 Million0.01% of portfolio
-
Janus Henderson Group PLC London, X07.17MShares$237 Million0.14% of portfolio
About BridgeBio Pharma, Inc.
- Ticker BBIO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 148,246,000
- Market Cap $4.91B
- Description
- BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabili...